Proficio Capital Partners LLC bought a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 21,303 shares of the biotechnology company's stock, valued at approximately $3,066,000.
Other institutional investors and hedge funds have also modified their holdings of the company. Resources Management Corp CT ADV acquired a new stake in Repligen in the 3rd quarter valued at about $37,000. Quarry LP raised its holdings in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 239 shares during the last quarter. UMB Bank n.a. raised its holdings in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 110 shares during the last quarter. Global Retirement Partners LLC raised its holdings in Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 129 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after acquiring an additional 90 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.
Wall Street Analyst Weigh In
RGEN has been the subject of a number of recent research reports. Evercore ISI initiated coverage on shares of Repligen in a report on Tuesday. They issued an "in-line" rating and a $155.00 price objective for the company. StockNews.com downgraded shares of Repligen from a "hold" rating to a "sell" rating in a report on Friday, February 21st. JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Canaccord Genuity Group raised their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a report on Friday, February 21st. Finally, Royal Bank of Canada raised their price target on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Repligen currently has a consensus rating of "Hold" and a consensus price target of $178.64.
Check Out Our Latest Research Report on Repligen
Insider Buying and Selling at Repligen
In other news, Director Margaret Pax acquired 250 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.
Repligen Stock Up 0.5 %
RGEN stock traded up $0.68 during midday trading on Friday, hitting $140.02. The company's stock had a trading volume of 623,142 shares, compared to its average volume of 650,573. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $200.03. The firm has a market capitalization of $7.86 billion, a P/E ratio of -274.55, a PEG ratio of 4.54 and a beta of 0.95. The firm has a 50-day simple moving average of $156.18 and a 200-day simple moving average of $148.32.
Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million during the quarter, compared to analysts' expectations of $167.58 million. As a group, equities analysts forecast that Repligen Co. will post 1.72 EPS for the current year.
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
